Laurus Labs gains on completing USFDA inspection at facility in Andhra Pradesh

05 Nov 2018 Evaluate

Laurus Labs is currently trading at Rs. 367.40, up by 2.10 points or 0.57% from its previous closing of Rs. 365.30 on the BSE.

The scrip opened at Rs. 365.00 and has touched a high and low of Rs. 367.90 and Rs. 365.00 respectively.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 579.25 on 22-Dec-2017 and a 52 week low of Rs. 330.30 on 26-Oct-2018.

Last one week high and low of the scrip stood at Rs. 368.00 and Rs. 340.00 respectively. The current market cap of the company is Rs. 3888.13 crore.

The promoters holding in the company stood at 33.40%, while Institutions and Non-Institutions held 47.70% and 18.89% respectively.

Laurus Labs has successfully completed the US Food and Drug Administration (USFDA) inspection of its unit-6 API intermediate facility with one observation, which is related to a procedure, on November 02, 2018.

The manufacturing facility unit-6 is located at Atchutapuram in Visakhapatnam, Andhra Pradesh and has 42 reactors with 253 kilo-liters capacity.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

586.40 15.60 (2.73%)
27-Dec-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1391.35
Cipla 1506.35
Lupin 2227.60
Zydus Lifesciences 972.45
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.